Research programme: sclerostin antibodies - Amgen/UCB
Latest Information Update: 16 Jul 2016
At a glance
- Originator Amgen; UCB
- Class Antibodies
- Mechanism of Action SOST protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bone resorption
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-resorption in USA (Parenteral)
- 05 Jul 2011 Preclinical trials in Bone resorption in USA (Parenteral)